About Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-2.8030303030303
Forward P/E Ratio-3.43
Sales & Book Value
Annual Sales$4 million
Price / Sales11.89
Price / CashN/A
Book Value($0.19) per share
Price / Book-9.74
Return on EquityN/A
Return on Assets-82.11%
Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions
What is Capricor Therapeutics' stock symbol?
Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."
How were Capricor Therapeutics' earnings last quarter?
Capricor Therapeutics Inc (NASDAQ:CAPR) posted its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.07. The biotechnology company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $1 million. Capricor Therapeutics's quarterly revenue was down 58.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.29) earnings per share. View Capricor Therapeutics' Earnings History.
When will Capricor Therapeutics make its next earnings announcement?
Where is Capricor Therapeutics' stock going? Where will Capricor Therapeutics' stock price be in 2018?
2 brokers have issued 12 month price objectives for Capricor Therapeutics' stock. Their predictions range from $2.15 to $8.60. On average, they anticipate Capricor Therapeutics' share price to reach $5.38 in the next twelve months. View Analyst Ratings for Capricor Therapeutics.
Who are some of Capricor Therapeutics' key competitors?
Some companies that are related to Capricor Therapeutics include Ergomed (ERGO), Verona Pharma (VRP), Gemphire Therapeutics (GEMP), KemPharm (KMPH), Leap Therapeutics (LPTX), Nexvet Biopharma (NVET), Pfenex (PFNX), MEI Pharma (MEIP), Flex Pharma (FLKS), Galmed Pharmaceuticals (GLMD), Aptevo Therapeutics (APVO), Axsome Therapeutics (AXSM), Applied Genetic Technologies (AGTC), Xenon Pharmaceuticals (XENE), Arcturus Therapeutics (ARCT), Versartis (VSAR), Rexahn Pharmaceuticals (RNN) and PLx Pharma (PLXP).
Who are Capricor Therapeutics' key executives?
Capricor Therapeutics' management team includes the folowing people:
- Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
- Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
- Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
- Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
- Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
- Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
- Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
- Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
- Deborah Ascheim M.D., Chief Medical Officer
- Joshua A. Kazam, Director (Age 40)
Who owns Capricor Therapeutics stock?
Capricor Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Brown Advisory Inc. (4.42%). Company insiders that own Capricor Therapeutics stock include Anthony Bergmann, Karen Krasney, Leland Gershell, Linda Marban, Louis J Grasmick, Louis Manzo and Sinai Medical Center Cedars. View Institutional Ownership Trends for Capricor Therapeutics.
Who bought Capricor Therapeutics stock? Who is buying Capricor Therapeutics stock?
Capricor Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Brown Advisory Inc.. Company insiders that have bought Capricor Therapeutics stock in the last two years include Anthony Bergmann, Karen Krasney, Leland Gershell, Linda Marban, Louis J Grasmick, Louis Manzo and Sinai Medical Center Cedars. View Insider Buying and Selling for Capricor Therapeutics.
How do I buy Capricor Therapeutics stock?
Shares of Capricor Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capricor Therapeutics' stock price today?
One share of Capricor Therapeutics stock can currently be purchased for approximately $1.85.
How big of a company is Capricor Therapeutics?
Capricor Therapeutics has a market capitalization of $47.56 million and generates $4 million in revenue each year. The biotechnology company earns $-18,800,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.
How can I contact Capricor Therapeutics?
Capricor Therapeutics' mailing address is 8840 Wilshire Blvd Fl 2, BEVERLY HILLS, CA 90211-2606, United States. The biotechnology company can be reached via phone at +1-310-3583200 or via email at [email protected]
MarketBeat Community Rating for Capricor Therapeutics (CAPR)MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Capricor Therapeutics (NASDAQ:CAPR) Earnings History and Estimates Chart
Capricor Therapeutics (NASDAQ CAPR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017||Q3 2017||($0.19)||($0.12)||$1.00 million||$0.31 million||View||N/A|
|8/10/2017||Q2 2017||($0.18)||($0.16)||$1.10 million||$1.00 million||View||N/A|
|5/15/2017||Q1 2017||($0.15)||($0.17)||$0.87 million||$0.88 million||View||N/A|
|3/15/2017||Q4 2016||($0.30)||($0.14)||$1.05 million||$0.91 million||View||N/A|
|11/10/2016||Q316||($0.27)||($0.29)||$1.12 million||$0.75 million||View||N/A|
|8/15/2016||Q2||($0.24)||($0.26)||$1.22 million||$1.13 million||View||Listen|
|5/12/2016||Q116||($0.19)||($0.26)||$1.10 million||$1.22 million||View||Listen|
|3/17/2016||Q415||($0.19)||($0.21)||$1.10 million||$1.12 million||View||N/A|
|11/12/2015||Q315||($0.26)||($0.18)||$1.10 million||$1.32 million||View||N/A|
|8/13/2015||Q215||($0.26)||($0.19)||$1.10 million||$1.29 million||View||N/A|
|5/12/2015||Q1 2015||($0.14)||($0.23)||$1.10 million||$1.79 million||View||N/A|
|3/18/2015||Q4 2014||($0.14)||($0.16)||$1.30 million||$1.40 million||View||N/A|
|11/13/2014||Q3 2014||($0.22)||($0.13)||$1.30 million||View||N/A|
|8/14/2014||Q2 2014||($0.13)||$1.04 million||View||N/A|
|5/15/2014||Q1 2014||($0.10)||$1.04 million||View||N/A|
Capricor Therapeutics (NASDAQ:CAPR) Earnings Estimates
Current Year EPS Consensus Estimate: $-0.54 EPS
Next Year EPS Consensus Estimate: $-0.54 EPS
Dividend History for Capricor Therapeutics (NASDAQ:CAPR)
No dividend announcements for this company have been tracked by MarketBeat.com
Capricor Therapeutics (NASDAQ CAPR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.50%
Institutional Ownership Percentage: 4.05%
Capricor Therapeutics (NASDAQ CAPR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/9/2017||Louis Manzo||Director||Buy||10,000||$3.10||$31,000.00||138,384|| |
|5/9/2017||Sinai Medical Center Cedars||Major Shareholder||Buy||1,145,161||$3.10||$3,549,999.10||4,049,959|| |
|9/21/2016||Sinai Medical Center Cedars||Major Shareholder||Buy||312,500||$3.20||$1,000,000.00||2,904,798|| |
|3/16/2016||Anthony Bergmann||VP||Buy||2,030||$2.40||$4,872.00||2,030|| |
|3/16/2016||Karen Krasney||EVP||Buy||4,060||$2.40||$9,744.00||11,156|| |
|3/16/2016||Leland Gershell||CFO||Buy||2,100||$2.40||$5,040.00||2,100|| |
|3/16/2016||Linda Marban||CEO||Buy||10,152||$2.40||$24,364.80|| |
|3/16/2016||Louis J Grasmick||Director||Buy||91,369||$2.40||$219,285.60|| |
|3/16/2016||Sinai Medical Center Cedars||Major Shareholder||Buy||416,666||$2.40||$999,998.40||2,592,298|| |
|8/20/2015||Louis J. Grasmick||Director||Buy||11,900||$4.11||$48,909.00||5,950|| |
|8/19/2015||Eduardo Marban||major shareholder||Buy||18,400||$4.36||$80,224.00||3,173,354|| |
|1/21/2015||Joshua A Kazam||Director||Buy||7,096||$3.52||$24,977.92|| |
|1/21/2015||Sinai Medical Center Cedars||Major Shareholder||Buy||851,546||$3.52||$2,997,441.92|| |
Capricor Therapeutics (NASDAQ CAPR) News Headlines
|Capricor Therapeutics (CAPR) Lowered to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - February 14 at 7:12 PM
|Capricor Therapeutics (CAPR) Upgraded at Zacks Investment Research|
www.americanbankingnews.com - February 13 at 7:00 PM
|Capricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular Dystrophy|
finance.yahoo.com - February 12 at 9:44 AM
|Pre-Open Movers 02/05: (CAPR) (EYES) (BG) Higher; (WFC) (DKS) (QCOM) Lower (more...)|
www.streetinsider.com - February 5 at 3:40 PM
|Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy|
finance.yahoo.com - February 5 at 3:40 PM
|BRIEF-Capricor Therapeutics Says FDA Has Granted CAP-1002 RMAT Designation|
www.reuters.com - February 5 at 9:34 AM
|Zacks Investment Research Downgrades Capricor Therapeutics (CAPR) to Hold|
www.americanbankingnews.com - February 2 at 6:42 PM
|Who Are Capricor Therapeutics Inc’s (NASDAQ:CAPR) Major Shareholders?|
finance.yahoo.com - January 30 at 3:43 PM
|Capricor Therapeutics (CAPR) Receives Buy Rating from HC Wainwright|
www.americanbankingnews.com - January 26 at 11:48 PM
| Capricor Therapeutics Inc (CAPR) Receives Consensus Rating of "Strong Buy" from Analysts|
www.americanbankingnews.com - January 24 at 5:42 PM
|Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies|
finance.yahoo.com - January 16 at 8:58 AM
| Capricor Therapeutics Inc (CAPR) Given Consensus Recommendation of "Strong Buy" by Brokerages|
www.americanbankingnews.com - December 30 at 7:46 AM
|Capricor Therapeutics (CAPR) versus Trevena (TRVN) Head to Head Review|
www.americanbankingnews.com - December 29 at 9:30 AM
|Market Trends Toward New Normal in Lockheed Martin, Silver Spring Networks, Capricor Therapeutics, Tupperware Brands, Eaton Vance, and Marcus & Millichap — Emerging Consolidated Expectations, Analyst Ratings|
finance.yahoo.com - December 18 at 8:58 AM
|ETFs with exposure to Capricor Therapeutics, Inc. : December 14, 2017|
finance.yahoo.com - December 14 at 5:23 PM
|Capricor Therapeutics Announces Issuance of Key US Patent on Exosome Technology - PR Newswire (press release)|
www.prnewswire.com - December 13 at 5:01 PM
|BRIEF-Capricor Therapeutics Announces Issuance Of Key U.S. Patent On Exosome Technology|
www.reuters.com - December 13 at 9:05 AM
|Capricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome Technology|
finance.yahoo.com - December 13 at 9:05 AM
|BRIEF-Capricor & California Institute For Regenerative Medicine Entered Into Amendment 3 To CIRM Notice Loan Award|
www.reuters.com - December 12 at 5:11 PM
|CAPRICOR THERAPEUTICS, INC. - StreetInsider.com|
www.streetinsider.com - December 12 at 10:30 AM
|Stock Review for Biotech's Investors -- Cyclacel Pharma, Capricor Therapeutics, Cymabay Therapeutics, and ... - PR Newswire (press release)|
www.prnewswire.com - December 11 at 5:01 PM
|Stock Review for Biotech's Investors -- Cyclacel Pharma, Capricor Therapeutics, Cymabay Therapeutics, and BioDelivery Sciences|
www.bizjournals.com - December 11 at 9:31 AM
|Capricor Therapeutics (CAPR) versus Its Rivals Critical Contrast|
www.americanbankingnews.com - December 8 at 7:46 PM
|Zacks: Analysts Set $6.50 Target Price for Capricor Therapeutics Inc (CAPR)|
www.americanbankingnews.com - December 8 at 3:48 AM
|How Does Capricor Therapeutics Inc’s (CAPR) EPS Growth Stack Up Against Industry Performance?|
finance.yahoo.com - December 6 at 5:56 PM
|Critical Contrast: Capricor Therapeutics (CAPR) & Its Rivals|
www.americanbankingnews.com - December 5 at 3:32 AM
|Active-Investors: Wired News - FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy|
www.finanznachrichten.de - December 1 at 4:15 PM
|Wired News – FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy|
finance.yahoo.com - December 1 at 4:15 PM
|ETFs with exposure to Capricor Therapeutics, Inc. : November 30, 2017|
finance.yahoo.com - November 30 at 4:49 PM
| Capricor Therapeutics, Inc. (CAPR) Given $6.50 Consensus Target Price by Analysts|
www.americanbankingnews.com - November 30 at 2:18 PM
|Capricor Soars on FDA Nod - Baystreet.ca|
www.baystreet.ca - November 30 at 9:00 AM
|Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002 - PR Newswire (press release)|
www.prnewswire.com - November 29 at 5:07 PM
|Capricor Therapeutics Inc (CAPR) Shares Soar on Back of FDA Investigational New Drug Clearance|
finance.yahoo.com - November 29 at 5:07 PM
|Capricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017|
finance.yahoo.com - November 29 at 10:09 AM
|Capricor Therapeutics stock rises 18% on FDA clearance for DMD clinical trial|
finance.yahoo.com - November 29 at 10:09 AM
|Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002|
finance.yahoo.com - November 29 at 8:50 AM
|Capricor: Risks Outweigh 'HOPE' - Seeking Alpha|
seekingalpha.com - November 25 at 3:47 PM
|Capricor Therapeutics (CAPR) and The Competition Head-To-Head Comparison|
www.americanbankingnews.com - November 25 at 1:22 AM
|Capricor Therapeutics (CAPR) Updates On Results from the HOPE-Duchenne Clinical Trial (12 months) - Slideshow|
seekingalpha.com - November 16 at 5:24 PM
|Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor's Investigational Cell Therapy|
finance.yahoo.com - November 16 at 12:25 PM
Capricor Therapeutics (NASDAQ:CAPR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Capricor Therapeutics (NASDAQ:CAPR) Income Statement, Balance Sheet and Cash Flow Statement
Capricor Therapeutics (NASDAQ CAPR) Stock Chart for Sunday, February, 18, 2018